The first and only approved treatment to target a genetic cause of amyotrophic lateral sclerosis (ALS)

QALSODY® (tofersen) is a prescription medicine used to treat adults with amyotrophic lateral sclerosis (ALS) who have a mutation, or change, in the superoxide dismutase 1 (SOD1) gene. QALSODY is approved under accelerated approval based on reduction in neurofilament light chain (NfL) in the blood observed in patients treated with QALSODY. Continued approval of QALSODY may require verification of clinical benefit in a confirmatory study.


Sign up to receive product information and
helpful resources.

Please enter a valid email address.